Prostatic Neoplasms, drug therapy

Name
Prostatic Neoplasms, drug therapy
Accession Number
DBCAT002819
Description

Not Available

Drugs
DrugDrug Description
ApalutamideAn androgen receptor inhibitor used to treat non-metastatic castration-resistant and metastatic castration-sensitive prostate cancer.
RelugolixAn oral GnRH receptor antagonist for androgen deprivation therapy in the treatment of advanced prostate cancer.
Drugs & Drug Targets
DrugTargetType
ApalutamideAndrogen receptortarget
ApalutamideCytochrome P450 3A4enzyme
ApalutamideCytochrome P450 2C8enzyme
ApalutamideCytochrome P450 2C19enzyme
ApalutamideCytochrome P450 2C9enzyme
ApalutamideP-glycoprotein 1transporter
ApalutamideATP-binding cassette sub-family G member 2transporter
ApalutamideSolute carrier organic anion transporter family member 1B1transporter
ApalutamideSolute carrier family 22 member 2transporter
ApalutamideSolute carrier family 22 member 8transporter
ApalutamideMultidrug and toxin extrusion protein 2transporter
ApalutamideGABA(A) Receptortarget
ApalutamideMultidrug and toxin extrusion protein 1transporter
ApalutamideSerum albumincarrier
RelugolixSerum albumincarrier
RelugolixAlpha-1-acid glycoprotein 1carrier
RelugolixP-glycoprotein 1transporter
RelugolixATP-binding cassette sub-family G member 2transporter
RelugolixCytochrome P450 3A Subfamilyenzyme
RelugolixCytochrome P450 2C8enzyme
RelugolixCytochrome P450 2B6enzyme
RelugolixGonadotropin-releasing hormone receptortarget